SEC Form 4 · accession 0000899243-16-035970
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lindsey Rolfe
Officer — See Remarks
Period of report
Dec 19, 2016
Accepted (ET)
Dec 19, 2016 · 6:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Dec 19, 2016 | A | 55,000 | A | — | — | Common Stock | 55,000 | 55,000 | D |
Explanation of responses
- F1Each restricted stock unit represents the right to receive one share of Common Stock.
- F2The restricted stock unit shall vest as to 25% of the units on December 19, 2017, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
Remarks
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance